Home Contact

logo

Family

Links:






Archives:


Newsletter:

Register for our Free monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.
Email
First Name
Last Name
Zip Code

Categories:



Register for our FREE monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.

Archive for September, 2008

Sergey Brin and Parkinson’s Disease

Friday, September 19th, 2008

Google co-founder Sergey Brin launched a personal blog Thursday, on which he revealed he has a genetic code that has been linked to having increased chances for developing Parkinson’s disease.

In the blog, too.blogspot.com, Brin says his mother and great aunt both were diagnosed with the degenerative brain disorder. Through 23andme Inc., a genetic testing organization, both Brin and his mother found they carry the G2019S mutation, which accounts for a substantial proportion of familial Parkinson’s, he wrote.

“The exact implications of this are not entirely clear,” Brin wrote in the blog. “Nonetheless, it is clear that I have a markedly higher chance of developing Parkinson’s in my lifetime than the average person.”

Brin deduced that he has a 20 percent to 80 percent higher-than-average chance to develop the disease, depending on the study and measurements.

“This leaves me in a rather unique position. I know early in my life something I am substantially predisposed to. I now have the opportunity to adjust my life to reduce those odds (e.g., there is evidence that exercise may be protective against Parkinson’s),” he wrote. “I also have the opportunity to perform and support research into this disease long before it may affect me. And, regardless of my own health, it can help my family members as well as others.”

Brin said he will help support research into the disease.

“I feel fortunate to be in this position,” he wrote. “Until the fountain of youth is discovered, all of us will have some conditions in our old age only we don’t know what they will be. I have a better guess than almost anyone else for what ills may be mine —and I have decades to prepare for it.”

EMEA Releases Guidelines On Development Of Medicines For Parkinson’s Disease

Monday, September 8th, 2008

The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer’s disease and other dementias, and for Parkinson’s disease, in the light of recent scientific progress in the understanding of these diseases and conditions.

Advances in clinical science, physiopathology and molecular biology have stimulated new interest in the development of more effective symptomatic or disease-modifying treatments, i.e. early treatments that may prevent the emergence or slow down the progression of disease. The guidelines were developed in response to the need of companies developing these new types of medicines for guidance on appropriate clinical-trial designs.

As life expectancy increases, neurodegenerative diseases and dementia will affect more and more people over the coming decades, and these guidelines are expected to help improve the availability of medicines to treat such diseases and conditions. The guidelines will come into effect on 1 February 2009.

(more…)